Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Grand Pharma Pays $17 Million for Wuhan Kernel Biotech

publication date: Sep 23, 2011
China Grand Pharmaceutical and Healthcare Holdings will pay 110 million RMB ($17.2 million) to acquire an 81% stake in Wuhan Kernel Biotechnology. Wuhan Kernel develops and sells bio-pesticides (most of which are exported) and feed additives. China Grand Pharma, headquartered in Hong Kong, makes drugs and APIs in its PRC-based subsidiaries, with a specialty in cardiovascular and ophthalmology drugs. More details....

Stock Symbol: (HK: 0512)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital